<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471003</url>
  </required_header>
  <id_info>
    <org_study_id>12729</org_study_id>
    <secondary_id>KL0601PL</secondary_id>
    <secondary_id>13929 - KL0601SI</secondary_id>
    <secondary_id>12804 - KL0601SK</secondary_id>
    <secondary_id>14326 - KL0601HR</secondary_id>
    <nct_id>NCT00471003</nct_id>
    <nct_alias>NCT00459095</nct_alias>
  </id_info>
  <brief_title>The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension</brief_title>
  <acronym>METABOLIC</acronym>
  <official_title>A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to asses the efficacy and safety of telmisartan, with the
      special attention on the influence of telmisartan on selected metabolic parameters of
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and safety of the treatment with telmisartan reported by the physician</measure>
    <time_frame>At the both of planned control visits. (Approx. interval between visits 3 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolic parameters in telmisartan treated patients</measure>
    <time_frame>At the both of planned control visits. (Approx. interval between visits 3 months)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5448</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pritor (Telmisartan , BAY68-9291)</intervention_name>
    <description>Primary care hypertensive patients starting the therapy with Telmisartan</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18

          -  Untreated or ineffectively treated arterial hypertension

        Exclusion Criteria:

          -  Cholestatic disorders and severe hepatic failure

          -  Allergy to telmisartan

          -  Pregnancy and lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2007</study_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Therapeutic Area Head</name_title>
    <organization>Bayer Sp. z o.o</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

